Celltrion Inc

Season’s greetings and warm wishes from everyone at Celltrion! 🎄 As we embrace the joy and warmth of the holiday season, our colleagues across the globe sends heartfelt thanks for your continued support and engagement. Wishing you a wonderful holiday season filled with peace and happiness! 🎁✨ #HappyHolidays Celltrion Healthcare France Celltrion Healthcare Italia Celltrion Healthcare BeLux Celltrion Healthcare Nederland

BREAKING NEWS: We are delighted to announce that the European Medicines Agency #CHMP has adopted a positive opinion recommending the approval of three #biosimilars from Celltrion. This will bring us one step closer to offering the patient-centric treatment for people living with various diseases in Europe. View press release here: https://bit.ly/3VF4DlG

#Biosimilars undergo a rigorous process to be approved by regulatory authorities. During the process, extrapolation plays a very important role in providing the data needed to prove the quality of the drug. Hear from Prof. João Manuel Braz Gonçalves, Full Professor in Faculty of Pharmacy at Universidade de Lisboa about the importance of extrapolation in regulatory approval of biosimilars.

We are excited to announce the launch of a new video series featuring distinguished physicians from around the world who have played a pivotal role in advancing treatments for respiratory and allergic diseases. In this series, we focus on biosimilars and their role in treating patients with these disease areas. In the first video, Prof. Jens Schreiber, MD, Head of Clinics for Pneumonology at University Hospital Magdeburg, explains what a #biosimilar is.

#Biosimilars offer significant benefits, including cost savings that make biologic therapies more accessible to patients. Today we would like to discuss more about the advantages biosimilars offer to enhance patient care and improve healthcare sustainability.

🔍💊#DYK the difference between #biosimilars and generics? As biosimilars are often confused with generics, we would like to highlight the key differences between them. Enhance your understanding and learn more about biosimilars!

This November, we invited global leading experts in #IBD to our state-of-the-art facility, equipped with cutting-edge technologies. The all-day visit included tour of the facility as well as networking opportunities. At Celltrion, we translate scientific innovation into medicines, to better meet the needs of our patients. A big thank you to everyone who took the time to attend – we hope you created lasting memories during your visit. 😊

Today, we announce the successful acquisition of iQone Healthcare Switzerland, a specialty pharmaceutical company focused on sales, marketing, and distribution in Switzerland.   This strategic acquisition will further solidify our market presence and portfolio, expediting our direct sales capabilities.   For more details, please view the press release here: http://bit.ly/4hRheeW

As we celebrate this year’s #GlobalBiosimilarsWeek, hear from our colleagues on how we can unlock the potential of biosimilars. 💡 Hear from Lucile Foulley and Brecht Steelant, who highlight the importance of collaboration among patients, physicians, health authorities, and payers to create a supportive environment for #biosimilars. Together, we can drive innovation and advance access to biosimilars.

Today we announced our Q3 2024 earnings release. Read full report at: https://bit.ly/4dBPTLc